Munro Partners Purchases Shares of 14,355 Insulet Corporation $PODD

Munro Partners acquired a new stake in shares of Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 14,355 shares of the medical instruments supplier’s stock, valued at approximately $4,510,000.

Other large investors have also made changes to their positions in the company. Marshall Financial Group LLC bought a new position in Insulet during the 2nd quarter valued at $943,000. Inspire Investing LLC raised its stake in shares of Insulet by 299.5% in the 1st quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier’s stock valued at $1,082,000 after purchasing an additional 3,088 shares in the last quarter. Illinois Municipal Retirement Fund lifted its position in shares of Insulet by 41.3% during the second quarter. Illinois Municipal Retirement Fund now owns 12,030 shares of the medical instruments supplier’s stock worth $3,780,000 after purchasing an additional 3,514 shares during the last quarter. Gradient Investments LLC acquired a new position in Insulet in the second quarter worth about $17,429,000. Finally, Goldman Sachs Group Inc. increased its holdings in Insulet by 1.9% in the first quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier’s stock valued at $152,130,000 after buying an additional 10,628 shares during the last quarter.

Analyst Ratings Changes

PODD has been the topic of a number of research analyst reports. Raymond James Financial increased their target price on Insulet from $366.00 to $385.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Barclays raised their price objective on Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Rothschild & Co Redburn boosted their target price on shares of Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Royal Bank Of Canada increased their target price on shares of Insulet from $370.00 to $380.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Finally, BTIG Research lifted their price target on shares of Insulet from $370.00 to $380.00 and gave the company a “buy” rating in a report on Friday, November 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $379.65.

Insulet Stock Performance

Shares of PODD opened at $295.70 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.18 and a current ratio of 2.87. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $354.88. The firm has a fifty day moving average of $318.88 and a 200-day moving average of $314.88. The company has a market cap of $20.80 billion, a price-to-earnings ratio of 85.71, a price-to-earnings-growth ratio of 2.08 and a beta of 1.37.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.11. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The business had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. During the same period in the previous year, the firm posted $1.08 earnings per share. The business’s revenue was up 29.9% on a year-over-year basis. As a group, equities analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.